Role of SUMO-1 and SUMO interacting motifs in rhesus TRIM5α-mediated restriction by Zana Lukic et al.
Lukic et al. Retrovirology 2013, 10:10
http://www.retrovirology.com/content/10/1/10RESEARCH Open AccessRole of SUMO-1 and SUMO interacting motifs in
rhesus TRIM5α-mediated restriction
Zana Lukic1†, Stephen P Goff2,3, Edward M Campbell1* and Gloria Arriagada2,3,4*†Abstract
Background: TRIM5α is a member of the tripartite motif family of proteins that restricts retroviral infection in a
species-specific manner. The restriction requires an interaction between the viral capsid lattice and the B30.2/SPRY
domain of TRIM5α. Previously, we determined that two SUMO interacting motifs (SIMs) present in the B30.2/SPRY
domain of human TRIM5α (huTRIM5α) were important for the restriction of N-tropic Murine Leukemia Virus. Here,
we examined whether SUMO expression and the SIM1 and SIM2 motifs in rhesus monkey TRIM5α (rhTRIM5α) are
similarly important for Human Immunodeficiency Type 1 (HIV-) restriction.
Results: We found that mutation of SIM1 and SIM2 of rhTRIM5α abolished the restriction of HIV-1 virus. Further,
knockdown of SUMO-1 in rhTRIM5α expressing cells abolished restriction of HIV-1. These results may be due, in
part, to the ability of SUMO-1 to stabilize rhTRIM5α protein expression, as SUMO-1 knockdown increased rhTRIM5α
turnover and the mutations in SIM1 and SIM2 led to more rapid degradation than the wild type protein. The NF-κB
signaling ability of rhTRIM5α was also attenuated by SUMO-1 knockdown. Finally, upon inhibition of
CRM1-dependent nuclear export with Leptomycin B (LMB), wild type rhTRIM5α localized to SUMO-1 bodies in the
nucleus, while the SIM1 and SIM2 mutants did not localize to SUMO-1.
Conclusions: Our results suggest that the rhTRIM5α B30.2/SPRY domain is not only important for the recognition
of the HIV-1 CA, but it is also important for its association with SUMO-1 or SUMO-1 modified proteins. These
interactions help to maintain TRIM5α protein levels and its nuclear localization into specific nuclear bodies.
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TRIM5α is a member of the TRIpartite Motif (TRIM)
family of proteins, characterized as having three domains:
a RING domain, either one or two B-box domains, and a
coiled-coil domain (RBCC) [1]. TRIM5α is capable of
restricting retroviral infection in a species-specific manner.
This restriction requires an interaction between the retro-
viral capsid (CA) lattice and the B30.2/SPRY domain of
TRIM5α [2-6]. The B30.2/SPRY domain, located at the C-
terminal of TRIM5α, confers the restriction spectrum of
TRIM5α proteins [6]. Human TRIM5α (huTRIM5α)* Correspondence: ecampbell@lumc.edu; gloria.arriagada@unab.cl
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reproduction in any medium, provided the orpotently restricts N-tropic murine leukemia virus (N-MLV)
but it does not restrict B-tropic or NB-tropic MLV
(B-MLV, NB-MLV respectively) [3,7]. On the other hand,
rhesus macaque TRIM5α (rhTRIM5α) restricts N-MLV
and human immunodeficiency type 1 (HIV-1) [6,8].
Small ubiquitin-related modifier (SUMO) proteins are
conjugated to cellular substrates and regulate diverse cellu-
lar processes (for review see [9,10]). SUMO proteins are
transferred to lysine residues within the UBC9 binding site
of the target protein. This binding site has a consensus se-
quence ΨKXE (where Ψ is a hydrophobic residue, K is the
lysine to which SUMO-1 is conjugated, X is any amino
acid and E is glutamic acid) [11,12]. Conjugation of SUMO
proteins to a substrate mediates distinct protein-protein
interactions in vivo. These non-covalent interactions with
SUMO modified proteins are mediated by SUMO interact-
ing motifs (SIMs) [11,13,14]. The best-characterized SIMs
have the consensus sequence V/I/L-x-V/I/L-V/I/L or V/I/
L-V/I/L-x-V/I/L (where x is any amino acid) [14,15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 SUMO interacting motifs are important for HIV-1
restriction by rhesus macaque TRIM5α. CRFK, TE671 and HeLa
cells were transduced with a retroviral vector encoding wild type
rhTRIM5α, SIM1mut, SIM2mut and SIM3mut or an empty vector (EV)
control. A. Western blot assay showing the expression of the FLAG-
tagged rhTRIM5α, using an anti-FLAG antibody, GAPDH was used as
a loading control. B-C. Cells stably expressing the various rhTRIM5α
proteins or an EV control were infected with an HIV-1 firefly
luciferase reporter virus pseudotyped with VSV-G envelope. 48 hours
after infection luciferase activity was measured. Representative
experiment of four independent experiments for CRFK (B), HeLa
(C) and TE671 (D) cells. E. The CRFK cells were infected with an
N-MLV firefly luciferase reporter virus pseudotyped with VSV-G
envelope. Representative experiment of four independent
experiments. Error bars show standard deviation between triplicates.
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system is involved in huTRIM5α- mediated restriction of
N-MLV [16]. Three SIMs were identified in the huTRIM5α
B30.2/SPRY domain. Two of them, SIM1 and SIM2, were
responsible for the enhanced restriction of N-MLV in
human cells observed upon SUMO-1 overexpression.
Specifically, mutation of SIM1 and SIM2 resulted in a
dramatic decrease in the ability of huTRIM5α to restrict
N-MLV infection. The SIMs are conserved among
TRIM5α orthologs, as the same SIM mutations also
affected the rhTRIM5α restriction of N-MLV [16]. As
such, we hypothesized that rhTRIM5α restriction of
HIV-1 was similarly dependent on SUMO-1 expression
and the SIM1 and SIM2 motifs of rhTRIM5α.
Here we report that SIMs are important for HIV-1 re-
striction, and that knockdown of SUMO-1 in rhTRIM5α
expressing cells drastically reduces HIV-1 restriction. We
hypothesize that the presence of SUMO-1 stabilizes pro-
teins levels of rhTRIM5α, as knockdown of SUMO-1
decreases steady state levels of rhTRIM5α and NF-κB acti-
vation. Additionally, mutation of the SIMs abolishes the
co-localization of rhTRIM5α with promyelocytic leukemia
protein (PML, also known as TRIM19)/SUMO-1 in the nu-
cleus upon LMB treatment. Our results suggest that the
rhTRIM5α B30.2/SPRY domain is not only important for
the recognition of the HIV-1 CA, but that it is also import-
ant for its association with SUMO-1 or with SUMO-1
modified proteins. This association helps maintain TRIM5α
protein levels, as well as its ability to mediate NF-κB, and
nuclear localization into specific nuclear bodies.
Results and discussion
Mutations in rhTRIM5α SIM1 and SIM2 motifs abolish HIV-1
restriction
To explore the importance of rhTRIM5α SIMs in restric-
tion of HIV-1, we generated CRFK, HeLa, and TE671 cell
lines stably expressing comparable levels of FLAG-tagged
wild type rhTRIM5α or the rhTRIM5α variants with
Figure 2 Restriction of HIV-1 by rhTRIM5α is reduced following
SUMO-1 knockdown. The TE671 empty vector control cell line or
the FLAG-rh TRIM5α expressing cell line were transduced with a
retroviral vector encoding a non-silencing shRNA (white bars), or a
SUMO-1 specific shRNA (black bars) and selected by antibiotic
resistance. A. The different cell lines were infected with an HIV-1
firefly luciferase reporter virus pseudotyped with VSV-G envelope.
48 hours post infection, luciferase activity was measured.
Representative experiment of three independent experiments. Error
bars show standard deviation between triplicates. B. RNA was
extracted, and the mRNA levels of SUMO-1 were determined by
quantitative PCR. The values were normalized to GAPDH mRNA and
expressed as fold over the respective non-silencing control. Error
bars indicate standard deviation between three different
quantifications.
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(430–433) (Figure 1A). These cell lines were infected with
VSV-G pseudotyped HIV-1 carrying a firefly luciferase re-
porter gene to assess retroviral restriction. The wild type
and SIM3 rhTRIM5α efficiently restricted HIV-1 infection
when compared to the empty vector (EV) in CRKF
(Figure 1B) and HeLa cells (Figure 1C). Conversely, muta-
tion of SIM1 and SIM2 of rhTRIM5α completely abolished
the restriction activity in these cell lines (Figure 1B, C).
Similar results were observed in TE671 cells (Figure 1D),
although the expression of the SIM1 and SIM2 mutants
was noticeably reduced compared to the expression of wild
type rhTRIM5α (Figure 1A). In all cell lines, mutation of
rhTRIM5α lysine 10 to arginine (K10R), a predicted
SUMOylation site had minimal effect on restriction, con-
sistent with our previous observations of huTRIM5α and
rhTRIM5α N-MLV restriction [16]. Similarly, in CRFK
cells, which do not express a functional TRIM5 gene [17],
the restriction of N-MLV by rhTRIM5α required a func-
tional SIM1 and SIM2, recapitulating the restriction profile
observed for HIV-1 (Figure 1E). Therefore, SIM1 and
SIM2 present in rhTRIM5α are important for its antiviral
activity against both N-MLV and HIV-1. Consistent with
this observation, another group has recently reported that
the SIM1 and SIM2 mutations disrupt the binding of
rhTRIM5α to the HIV-1 capsid [18].
Restriction of HIV-1 by rhTRIM5α is reduced following
SUMO-1 knockdown
To determine if the ability of rhTRIM5α to restrict HIV-1
infection was dependent on interactions with SUMO-1, we
stably knocked down SUMO-1 (SUMO-1 KD) using a
SUMO-1 specific shRNA in TE671 cells expressing FLAG-
rhTRIM5α or empty vector. A non-silencing shRNA was
used as a control. To confirm SUMO-1 KD, we performed
quantitative PCR (qPCR) and found that these cells had
~70% SUMO-1 KD (Figure 2B). Control cells transduced
with empty vector did not show appreciable differences in
HIV-1 infection following SUMO-1 KD (Figure 2A). Cells
transduced to express FLAG-rhTRIM5α showed consider-
able restriction of HIV-1. Notably, following SUMO-1 KD
the restriction activity of cells expressing FLAG-rhTRIM5α
was reduced to levels similar to cells expressing empty
vector (Figure 2A). This demonstrates that rhTRIM5α re-
striction of HIV-1 is sensitive to SUMO-1 depletion.
SUMO-1 enhances rhTRIM5α stability in cells
As noted earlier, TE671 cells expressing rhTRIM5α SIM
mutants showed reduced expression compared to TE671
cell lines expressing wild type or K10R forms of rhTRIM5α
(Figure 1A). This suggests that disrupting interactions with
SUMO-1 may increase the turnover of rhTRIM5α. It was
previously reported that knockdown of host cellular pro-
teins which interact with rhTRIM5α increased rhTRIM5α
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sion levels by Western blot following SUMO-1 siRNA
treatment in a HeLa cell line stably expressing HA-
rhTRIM5α [8]. In these cells, SUMO-1 KD reduced HA-
rhTRIM5α expression (Figure 3), although this reduction
did not correlate with the degree of restriction observedFigure 3 SUMO-1 enhances rhTRIM5α stability in cells. A. HeLa cells st
SUMO-1 or a non-targeting siRNA. Cells were rested for 24 or 48 hours pos
for SUMO-1, HA-rhTRIM5α and β-actin. Representative Western blot image
on SUMO-1 protein levels. SUMO-1 densitometry in SUMO-1 siRNA treated
densitometry analysis using ImageJ on HA-rhTRIM5α protein levels. Densito(Figure 2B). Other studies have noted that small alterations
in TRIM5α expression do not dramatically affect restriction
activity at non-saturating amounts of virus [4,20]. These
observations make it difficult to separate the contribution
of reduced protein expression and the relief of restriction
observed in studies of this type. Therefore, it remainsably expressing HA-rhTRIM5α were transfected with siRNA targeting
t transfection. Cell lysates were collected and analyzed by Western blot
of 5 independent experiments. B. Densitometry analysis using ImageJ
cells was normalized to control siRNA treated cells. C. HA-rhTRIM5α
metry was normalized as in B.
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not entirely due to reduced expression of rhTRIM5α.
NF-κB activation by rhTRIM5α is sensitive to SUMO-1
expression
Recent studies have shown that TRIM5 proteins can acti-
vate intracellular signaling pathways that culminate in AP-
1 and NF-κB activation [21,22]. In order to understand the
role of SUMO-1 and SIMs in rhTRIM5α-mediated signal-
ing, we transiently expressed wild type and rhTRIM5α
mutants along with an NF-κB luciferase reporter. Both the
wild type and SIM3 mutant form of rhTRIM5α were able
to activate NF-κB. On the other hand, the SIM1 and SIM2Figure 4 The role of SIMs and SUMO-1 expression on NF-κB activatio
empty vector (EV), ΔRING/SPRY rhTRIM5α (ΔRS), wild typerhTRIM5α, SIM m
A renila luciferase construct was used as an internal transfection efficiency
activity was measured. NF-κB luciferase readings were normalized to renilla
Upper panel, representative luciferase activity in the presence of various co
panel,representative Western blot. Representative of 4 independent experim
mutants with a FLAG-tag or an EV. Cells weretransiently transfected with an
panel, NF-κB luciferase activity in the presence of rhTRIM5α mutants. Error
panel, representative Western blot at the time of data acquisition. C. 293T c
hours. Cells were then seeded in a 96-well plate in triplicate and transfecte
measured as in A. Data were plotted by dividing SUMO-1 siRNA activation
<0.004 by Student’s t-test. Error bars represent the SEM between the triplic
were transfected with empty vector, and wild type rhTRIM5α constructs in
A. Data were plotted as in C. Error bars represent the SEM between triplicamutants did not induce significant signaling above back-
ground in this context (Figure 4A, top panel). However,
following transient transfection, the protein expression
levels of the SIM1 and SIM2 mutants were reduced com-
pared to wild type and SIM3 mutants, possibly explaining
the loss of NF-κB activation (Figure 4A, bottom panel). To
assess NF-κB signaling by rhTRIM5α SIM mutants at com-
parable protein levels, we generated 293A cell lines stably
expressing wild type rhTRIM5α and the SIM mutants and
measured NF-κB activation in these cells. Under these con-
ditions, when the SIM mutants were expressed at compar-
able levels to wild type rhTRIM5α, they elicited similar
levels of NF-κB activation (Figure 4B). Consistent with an by rhTRIM5α. A. 293T cells plated in triplicate were transfected with
utants or RIG-I along with NF-κB-responsive firefly luciferase construct.
control. 48-hours post transfection, cells were lysed and luciferase
luciferase, and plotted as an average fold increase over empty vector.
nstructs.Error bars represent the SEM between the triplicates. Lower
ents. B. 293A stably expressing wild typerhTRIM5α, K10R mut, SIM
NF-κB firefly luciferase and renila luciferase plasmids as in A. Upper
bars represent the SD between 3 independent experiments. Lower
ells were transfected with Control siRNA or SUMO-1siRNA for 48
d with empty vector or wild type rhTRIM5α. NF-κB activity was
by control siRNA activation x 100. Inset, representative Western blot. P
ates. Data is representative of 3independent experiments. D. 293T cells
presence and absence of SUMO-1. NF-κB activity was measured as in
tes. Representative of 3 independent experiments.
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these mutants [18], and the data here that demonstrate the
ability of these mutants to activate NF-κB, we conclude
that the defect in restriction by rhTRIM5α SIM mutants is
not due to gross misfolding of the protein.
We next asked how SUMO-1 depletion affected the
ability of wild type rhTRIM5α to induce NF-κB activation.
We co-transfected 293T cells with wild type HA-
rhTRIM5α, SUMO-1 or control siRNA and an NF-κB
driven luciferase reporter. We measured NF-κB activation
by rhTRIM5α in SUMO-1 siRNA treated cells compared
to rhTRIM5α cells treated with control siRNA. As shown
in Figure 4C knocking down SUMO-1 had little effect on
NF-κB activation when transfected with EV (~10%, black
bar). However, depletion of SUMO-1 significantly reduced
(~60%, p<0.004, Student’s T-test) NF-κB activation by wild
type rhTRIM5α (Figure 4C, grey bar). The reduction of
NF-κB activation in the presence of SUMO-1 siRNA was
not due to reduced rhTRIM5α protein levels (Figure 4C
inset) as SUMO-1 knockdown does in cells stably expres-
sing rhTRIM5α (Figure 3). Conversely, overexpression of
SUMO-1 increased NF-κB activation following transfec-
tion with empty vector or vector expressing wild type
rhTRIM5α (Figure 4D). This increase was more pro-
nounced when rhTRIM5α was present, although this
result was not statistically significant (p=0.187, Student
T-test). These experiments demonstrate that the ability to
associate with SUMO-1 or SUMOylated proteins is rele-
vant to rhTRIM5α-mediated NF-κB signaling.Figure 5 SUMO-1 antibody recognizing cytoplasmic SUMO-1 does no
expressing YFP-rhTRIM5α were immunostained with a mouse anti-SUMO-1
area that was zoomed in to create the bottom panel. White arrows point t
contain SUMO-1.The SIM1 and SIM2 mutations disrupt rhTRIM5α
trafficking to nuclear bodies containing PML and SUMO-1
We next analyzed the association of rhTRIM5α and
SUMO-1 by immunofluorescence to verify that SIM1 and
SIM2 do not interact with SUMO-1 or SUMO-1 modified
proteins. In HeLa cells stably expressing YFP-rhTRIM5α,
we examined the co-localization of rhTRIM5α and en-
dogenous SUMO-1. We used two antibodies to SUMO-1
to examine both the cytoplasmic and nuclear fractions of
SUMO-1. The first antibody (GMP1, clone 21C7) recog-
nized nuclear SUMO-1 as well as numerous cytoplasmic
puncta. However, the cytoplasmic SUMO-1 did not co-
localize with YFP-rhTRIM5α (Figure 5). When these cells
were stained with an antibody to PML, we did not observe
significant localization of SUMO-1 to PML (data not
shown). As SUMO-1 positive structures in the nucleus are
well characterized and known to contain PML [23,24], we
used a second antibody (clone Y299) that recognized nu-
clear structures that were PML positive (Data not shown).
This antibody detected primarily diffuse and punctate nu-
clear SUMO-1. We used this antibody in subsequent
experiments to examine SIM1 and SIM2 localization with
SUMO-1. A recent study demonstrated that while steady
state rhTRIM5α is excluded from the nucleus, it can transi-
ently enter and exits the nucleus, where it associates with
PML bodies. This nuclear localization of rhTRIM5α to
PML bodies is observed when the nuclear export of
rhTRIM5α is inhibited with Leptomycin B (LMB), which is
an inhibitor of CRM1 mediated nuclear export [25].t localize to rhTRIM5α cytoplasmic bodies. HeLa cells stably
(GMP1) clone 21C7. The white box in the top panel represents the
o representative rhTRIM5α cytoplasmic bodies that do not
Figure 6 (See legend on next page.)
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Figure 6 The SIM1 and SIM2 mutations disrupt rhTRIM5α localization to nuclear bodies containing PML/TRIM19 andSUMO-1. A. HeLa
cells stably expressing wild typeYFP-rhTRIM5α or SIM mutants were treated with LMB for 4 hours. Following treatment the cells were fixed and
imaged. Z-stack images were collected with a DeltaVision microscope equipped with a digital camera using a 1.4-numerical aperture (NA) 100×
objective lens, and were deconvolved with SoftWoRx deconvolution software. Individual channel images were superimposed to create the
merged panels. B. HeLa cells expressing wild type YFP-rhTRIM5a or SIM mutants were treated with LMB for 4hours. Following treatment the cells
were fixed and stained with an anti-SUMO-1 antibody. Z-stack images were collected as described in A. Deconvolved images were analyzed for
YFP-rhTRIM5a maximum fluorescence intensity (MFI) in SUMO-1nuclear bodies by the use of the Surface Finder function in the Imaris software
(Bitplane). For each SUMO-1 puncta, the MFI of YFP-rhTRIM5a mutants was determined and the data was plotted in GraphPad Prism 5W software.
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revealed that wt and all three SIM mutants localized to the
nucleus (Figure 6A), contrary to a recent report by another
group which found that the SIM1 and SIM2 mutants did
not localize to the nucleus under these conditions [18].
However, when we quantified the localization of these
mutants to nuclear SUMO-1 bodies, SIM1 and SIM2
mutants of rhTRIM5α failed to localize to SUMO-1 positive
bodies when nuclear export is inhibited, while the SIM3
mutant associated with these bodies to an intermediate de-
gree (Figure 6B). These SUMO-1 positive rhTRIM5α nu-
clear bodies were also positive for PML (data not shown).
Potential mechanisms of SUMO-1 regulation of rhTRIM5α
Collectively, the data presented here demonstrate that SIMs
in rhTRIM5α and SUMO-1 are important for rhTRIM5α-
mediated retroviral restriction. rhTRIM5α is sensitive to
changes in SUMO-1 expression as SUMO-1 knockdown
relieves rhTRIM5α restriction (Figure 2) and increases
rhTRIM5α protein turnover in stable cells (Figure 3). Add-
itionally, SUMO-1 modulates rhTRIM5α-dependent acti-
vation of NF-κB (Figure 4). Upon SUMO-1 knockdown,
NF-κB activation is decreased in a rhTRIM5α-dependent
manner (Figure 4C). We also observed decreased localization
of SIM1 and SIM2 to SUMO-1 puncta following LMB treat-
ment (Figure 6).
The mechanism by which SUMO-1 stabilizes rhTRIM5α
expression or affects retroviral restriction is unclear. It is
possible that rhTRIM5α interacts with a protein that stabi-
lizes its expression in a SUMO-dependent manner. It is
also possible that the expression of another cellular protein
that is stabilized by SUMOylation, stabilizes rhTRIM5α ex-
pression. Consistent with this, it is known that SUMOyla-
tion can protect some proteins from ubiquitin dependent
degradation [26]. Our observation that the SIM1 and SIM2
mutations, which abrogate restriction, are also turned over
more rapidly than wild type rhTRIM5α are consistent with
all of these possibilities. Interestingly, a recent study by
Brandariz-Nunez et al. suggests that these residues are not
present on the surface of the SPRY domain [18], as mod-
eled using an NMR structure recently described for the
PRY/SPRY domain [27]. It may be that conformational
changes induced by the binding of other cellular factors
conditionally expose the SIM1 and SIM2 motifs. These
authors also observe that SIM1 and SIM2 mutantsoligomerize normally [18], suggesting these proteins are
not misfolded. While we cannot exclude the possibility that
SIM1 and SIM2 mutations prevent proper folding of the
B30.2/SPRY domain, our own results demonstrate that
alterations in SUMO-1 expression can influence the stabil-
ity of wild type rhTRIM5α.
The data presented here may begin to explain the mech-
anistic of rhTRIM5α nuclear trafficking. It is possible that
the recruitment of TRIM5α to SUMO-1/PML bodies has
direct relevance to the restriction process, as both the SIM1
and SIM2 mutants that do not localize to SUMO-1/PML
bodies are completely unable to restrict retroviral infection.
Considering that PML protein undergoes SUMOylation on
three lysine residues [28-30] and rhTRIM5α has a rapid
turnover [31], we can speculate that the steady state levels of
rhTRIM5α protein are maintained by its interaction via
SIMs with SUMOylated-PML in the nucleus. When SIMs
or SUMO-1 are not present rhTRIM5α is less retained in
the nucleus and therefore is degraded faster in the cytosol,
reducing the amount of protein available to restrict incom-
ing viruses.
Interestingly, owl monkey TRIM-Cyp, which contains a
C-terminal cyclophilin A domain instead of a B302/SPRY
domain (the B30.2/SPRY domain contains all three puta-
tive SIMs) [32], does not traffic to the nucleus [25]. There-
fore, given the strong homology between the RBCC
domains of owl monkey TRIM-Cyp and rhTRIM5α, it is
possible that the SPRY domain contains the determinants
that govern nuclear trafficking. Consistent with this hypoth-
esis, our data demonstrate that wild type rhTRIM5α, but
not the SIM1 and SIM2 mutants, localizes to nuclear
SUMO-1 bodies (Figure 5) support this idea. Although the
results we have obtained using the SIM1 and SIM2 mutants
were consistent with the effect of SUMO-1 knockdown on
wild type rhTRIM5α activity, the results obtained with these
mutants should be cautiously interpreted [18].
Future studies are needed to determine if this associ-
ation is merely correlative or the association of rhTRIM5α
with nuclear SUMO-1/PML bodies potentiates specific
steps in the restriction process.
Conclusions
Our results demonstrate that rhTRIM5α restriction and
expression is governed by SUMO-1 expression. SUMO-1
depletion, or mutations that are expected to disrupt
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rate of rhTRIM5α turnover. The ability of rhTRIM5α to ac-
tivate innate immune signaling pathways is also sensitive to
SUMO-1 expression. Additionally, the ability to traffic to
nuclear SUMO-1 bodies is abrogated by mutation of the
SIM1 or SIM2 motifs present in rhTRIM5α. As rhTRIM5α
does not appear to itself be SUMOylated, future studies
are needed to identify the cellular factor or factors that are
likely regulating rhTRIM5α in a SUMO-1 dependent
fashion.
Methods
Cell lines and plasmids
Human embryonic fibroblast 293T, 293A, human medul-
loblastoma cell line TE671, HeLa and Crandall feline kid-
ney (CRFK) fibroblast were maintained in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bo-
vine serum, 100 UI/ml penicillin and 100 mg/ml strepto-
mycin. All cells were cultured at 37°C in 5% CO2.
The rhTRIM5α constructs encoding the FLAG tagged
wild type and mutant versions were identified and cloned
as previously described [16]. YFP tagged wild type and
mutant versions were cloned into a retroviral vector previ-
ously described [33]. RIG-I construct was kindly donated
to us by Dr. Susan Baker (Loyola University Chicago).
Generation of stable cell lines
Retroviruses for transduction were produced by transfec-
tion of 293T cells with 1 μg pMD.G, 1 μg pCMVI and 1.5
μg of either pQCXIN, pQCXIN-FLAG-rhTRIM5α wild-
type or mutant versions, using FUGENE (Roche). Viruses
were harvested 48 h after transfection, filtered (0.45 μm)
and used to infect 5x105 cells in 100 mm dishes in the
presence of 8 μg/ml polybrene. HeLa, TE671, 293A cells
infected with vectors delivering the Neor gene were
selected in 1.5 μg/ml G418. The CRFK cells overexpres-
sing rhTRIM5α were previously described [16]. Lenti-
viruses for transduction were produced by transfection of
293T cells with 1 μg pMD.G, 1 μg p8.91 and 1.5 μg of
pGIPz (Open Biosystems) or pGIPzSUMO-1 DNAs con-
taining shRNA (Open Biosystems). Viruses were harvested
48 h after infection, filtered (0.45 μm) and used to infect
5x104 TE671-rhTRIM5α cells in 35 mm dishes in the
presence of 8 μg/ml polybrene. Cells were selected in 1.5
μg/ml G418 and 1.5 μg/ml puromycin.
Western blotting
Cells were lysed in 20 mMTris-HCl (pH 8.0), 137
mMKCl, 10% glycerol, 1% NP-40 and complete protease
inhibitor (Roche) or Reporter lysis buffer (Promega).
Samples were then boiled in 5x sodium dodecyl sulphate
(SDS) loading buffer, and the proteins were resolved by
SDS-polyacrylamide gel electrophoresis (PAGE). After
transfer to nitrocellulose membranes, the blots wereprobed with mouse anti-β actin (Sigma), anti-HA (Cov-
ance), anti SUMO-1 (Abcam clone Y299), anti-FLAG
(Sigma) or anti-GAPDH (Calbiochem).
Single-cycle infectivity assay
HIV-1 luciferase reporter virus was produced by transfec-
tion of 293T cells with 2μg pNL4.3-env luciferase, and 1 μg
pMD.G (per 100 mm plate) using FUGENE (Roche).
Reporter virus stocks were harvested 48 h after transfection,
then filtered (0.45 μm) and stored at −80°C. 293A (3x104
per well), HeLa (2.5x104 per well), TE671 (2.5x104 per well)
and CRFK (3x104 per well) cells were seeded in 24-well
plates and infected with MLV luc reporter viruses. Forty-
eight hours post-infection cells were collected and assayed
for firefly luciferase activity (Promega) in a luminometer.
Analysis of SUMO-1 knock down
In the case of the TE671 cells where SUMO-1 was stably
knocked down, the cells were harvested and total RNA
was extracted using TRIZOL reagent (Invitrogen). 2 μg of
total RNA per cell line were used to produce cDNA using
random hexamers and SuperScript III kit (Invitrogen).
2 μl of each cDNA were used for quantitative PCR analysis
of SUMO-1 and GAPDH transcript levels. Fold change
was calculated using the relative standard curve method.
For the transient knockdown of SUMO-1, HeLa cells
stably expressing HA-rhTRIM5α were transfected with
siRNA specifically targeting SUMO-1 or a non-targeting
siRNA (Santa Cruz Biotechnology). Cells were transfected
with Lipofectamine2000 (Invitrogen) using a 2-day trans-
fection protocol followed by 24-hours or 48-hours of rest
to gain maximum knockdown efficiency. Cells were col-
lected following the resting period and analyzed by
western blot using a monoclonal anti-SUMO-1 antibody
(Abcam clone Y299). Densitometry analysis was per-
formed on the western blots using ImageJ software.
Immunofluorescence
HeLa cells transfected with wild type YFP-rhTRIM5α and
SIM mutants (Lipofectamine2000 protocol) were allowed
to adhere to fibronectin-treated glass coverslips. Cells were
treated with LMB for 4 hours and fixed with 3.7% formal-
dehyde (Polysciences) in 0.1 M PIPES, pH 6.8 [piperazine-
N, N'-bis(2-ethanesulfonic acid)] (Sigma). Monoclonal
rabbit anti-SUMO-1 (Abcam clone Y299) antibody was
used to stain SUMO-1. Primary antibody was secondarily
labeled with Cy5 fluorophore-conjugated donkey anti-
mouse antibody (Jackson ImmunoResearch). Nucleus was
stained using a DAPI stain (Jackson ImmunoResearch).
Images were collected with a DeltaVision microscope (Ap-
plied Precision) equipped with a digital camera (CoolSNAP
HQ; Photometrics), using a 1.4-numerical aperture 100×
objective lens, and they were deconvolved with SoftWoRx
deconvolution software (Applied Precision).
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20 Z-stack images were acquired using identical acquisi-
tion parameters. Surfaces for cytoplasmic bodies in all
samples analyzed were defined by using a fluorescence
threshold for YFP-rhTRIM5α, and all YFP-rhTRIM5α
bodies over a volume of 0.011 μm3 were used in the ana-
lysis. Deconvolved images were analyzed for SUMO-1
maximum fluorescence intensity (MFI) in cytoplasmic
bodies using the Surface Finder function of the Imaris
software package (Bitplane) and the data was plotted in
Prism (Graphpad Software Inc) for statistical analysis.
Dual-luciferase reporter assay
SIMs
293T cells seeded in a 96-well plate were transfected with
empty vector, ΔRING/SPRY rhTRIM5α (ΔRS, negative
control), wild type rhTRIM5α, SIM1 mut, SIM2 mut,
SIM3 mut or RIG-1 (positive control) in triplicate. Trans-
fection was carried out using polyethylenimine (PEI)
protocol in which the constructs were added at a 9 (EV/
rhTRIM5α/RIG-I): 3 (NF-kB-responsive firefly luciferase
construct): 1 (Renilla luciferase construct for transfection
efficiencies) ratio. Cells were lysed 48-hours post transfec-
tion with Passive lysis buffer (Promega) and the luciferase
activity was measured using a Dual-Glo luciferase assay
system (Promega) in a Veritas Microplate luminometer.
Firefly luciferase data were normalized to Renilla luciferase
readings in each well. Data were plotted by determining
the fold increase over empty vector.
SUMO-1 overexpression
293T cells seeded in a 96-well plate were transfected with
empty vector, and rhTRIM5α constructs in presence or
absence of SUMO-1 in triplicate. Transfection was carried
out using PEI protocol in which the constructs were added
at a 5 (rhTRIM5α): 4 (SUMO-1 or EV): 3 (NF-κB-respon-
sive firefly luciferase construct): 1 (Renilla luciferase con-
struct for normalization of transfection efficiencies) ratio.
Cells were lysed 48-hours post transfection with Passive
lysis buffer (Promega) and the luciferase activity was mea-
sured using a Dual-Glo luciferase assay system (Promega)
in aVeritas Microplate luminometer. Firefly luciferase data
were normalized to Renilla luciferase readings in each
well. Data were plotted by dividing SUMO-1 siRNA NF-
κB activation by Control siRNA NF-κB activation x 100.
SUMO-1 knockdown
293T cells seeded in a 12-well plate were transfected with
Control siRNA or SUMO-1 siRNA (Santa Cruz Biotech-
nology, Inc) following a Lipofectamine2000 (Invitrogen)
protocol for two days. On the third day the cells were
seeded in a 96-well plate in triplicate and transfected with
empty vector or wild type rhTRIM5α using PEI in which
constructs were added at a 9 (EV/rhTRIM5α): 3 (NF-kB-responsive firefly luciferase construct): 1 (Renilla luciferase
construct for transfection efficiencies) ratio. Cells were
lysed 48-hours post transfection with Passive lysis buffer
(Promega) and the luciferase activity was measured using
a Dual-Glo luciferase assay system (Promega) in a Veritas
Microplate luminometer. Firefly luciferase data were nor-
malized to Renilla luciferase readings in each well. Data
were plotted by dividing SUMO-1 siRNA NF-κB activa-
tion by Control siRNA NF-κB activation x 100.
Abbreviation
SUMO: Small ubiquitin-related protein; SIM: SUMO-interacting motif;
rhTRIM5α: Rhesus monkey TRIM5α; HIV-1: Human immunodeficiency virus;
KD: Knocked down.
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